Andrew M Moon1, Stephanie E Watkins2, Anna S Lok3, Roberto J Firpi-Morell4, Huy Ngoc Trinh5, Justin T Kupec6, Cheryl Schoen2, Brent A Neuschwander-Tetri7, A Sidney Barritt8. 1. Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, UNC Liver Center, Chapel Hill, North Carolina, USA, Andrew.Moon@unchealth.unc.edu. 2. TARGET PharmaSolutions, Inc., Durham, North Carolina, USA. 3. Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA. 4. Section of Hepatobiliary Diseases and Transplantation, University of Florida, Gainesville, Florida, USA. 5. San Jose Gastroenterology, San Jose, California, USA. 6. Department of Medicine, Section of Digestive Diseases, West Virginia University, Morgantown, West Virginia, USA. 7. Division of Gastroenterology and Hepatology, Saint Louis University, St. Louis, Missouri, USA. 8. Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, UNC Liver Center, Chapel Hill, North Carolina, USA.
Abstract
BACKGROUND: Opioid use is a topic of growing concern among patients with nonalcoholic fatty liver disease (NAFLD). Given safety concerns of opioids, proactively identifying subgroups of patients with an increased probability of opioid use may encourage practitioners to recommend alternative therapies for pain, thus reducing the likelihood of opioid misuse. This work assessed the prevalence and patient characteristics associated with opioid use in a real-world cohort of patients with NAFLD. METHODS: TARGET-NASH, an observational study of participants at 55 academic and community sites in the United States, includes patients with NAFLD defined by pragmatic case definitions. Opioid use was defined as any documented opioid prescriptions in the year prior to enrollment. The association between patient characteristics and the odds of opioid use were modeled with stepwise multivariable logistic regression and tree ensemble methods (Classification and regression tree/Boosted Tree). RESULTS: The cohort included 3,474 adult patients with NAFLD including 18.0% with documented opioid use. Variables associated with opioid use included presence of cirrhosis (OR 1.51, 95% CI 1.16-1.98), BMI ≥32 kg/m2 (OR 1.29, 95% CI 1.05-1.59), depression (OR 1.87, 95% CI 1.50-2.33), and anxiety (OR 1.59, 95% CI 1.27-1.98). In the boosted tree analysis, history of back pain, depression, and fibromyalgia had the greatest relative importance in predicting opioid use. CONCLUSION: Prescription opioids were used in nearly 1 of 5 patients with NAFLD. Given the safety concerns of opioids in patients with NAFLD, alternative therapies including low-dose acetaminophen and nonpharmacologic treatments should be considered for these patients.
BACKGROUND: Opioid use is a topic of growing concern among patients with nonalcoholic fatty liver disease (NAFLD). Given safety concerns of opioids, proactively identifying subgroups of patients with an increased probability of opioid use may encourage practitioners to recommend alternative therapies for pain, thus reducing the likelihood of opioid misuse. This work assessed the prevalence and patient characteristics associated with opioid use in a real-world cohort of patients with NAFLD. METHODS: TARGET-NASH, an observational study of participants at 55 academic and community sites in the United States, includes patients with NAFLD defined by pragmatic case definitions. Opioid use was defined as any documented opioid prescriptions in the year prior to enrollment. The association between patient characteristics and the odds of opioid use were modeled with stepwise multivariable logistic regression and tree ensemble methods (Classification and regression tree/Boosted Tree). RESULTS: The cohort included 3,474 adult patients with NAFLD including 18.0% with documented opioid use. Variables associated with opioid use included presence of cirrhosis (OR 1.51, 95% CI 1.16-1.98), BMI ≥32 kg/m2 (OR 1.29, 95% CI 1.05-1.59), depression (OR 1.87, 95% CI 1.50-2.33), and anxiety (OR 1.59, 95% CI 1.27-1.98). In the boosted tree analysis, history of back pain, depression, and fibromyalgia had the greatest relative importance in predicting opioid use. CONCLUSION: Prescription opioids were used in nearly 1 of 5 patients with NAFLD. Given the safety concerns of opioids in patients with NAFLD, alternative therapies including low-dose acetaminophen and nonpharmacologic treatments should be considered for these patients.
Authors: Jason W Busse; Li Wang; Mostafa Kamaleldin; Samantha Craigie; John J Riva; Luis Montoya; Sohail M Mulla; Luciane C Lopes; Nicole Vogel; Eric Chen; Karin Kirmayr; Kyle De Oliveira; Lori Olivieri; Alka Kaushal; Luis E Chaparro; Inna Oyberman; Arnav Agarwal; Rachel Couban; Ludwig Tsoi; Tommy Lam; Per Olav Vandvik; Sandy Hsu; Malgorzata M Bala; Stefan Schandelmaier; Anne Scheidecker; Shanil Ebrahim; Vahid Ashoorion; Yasir Rehman; Patrick J Hong; Stephanie Ross; Bradley C Johnston; Regina Kunz; Xin Sun; Norman Buckley; Daniel I Sessler; Gordon H Guyatt Journal: JAMA Date: 2018-12-18 Impact factor: 56.272
Authors: Leon A Adams; James F Lymp; Jenny St Sauver; Schuyler O Sanderson; Keith D Lindor; Ariel Feldstein; Paul Angulo Journal: Gastroenterology Date: 2005-07 Impact factor: 22.682
Authors: Mina O Rakoski; Ryan J McCammon; John D Piette; Theodore J Iwashyna; Jorge A Marrero; Anna S Lok; Kenneth M Langa; Michael L Volk Journal: Hepatology Date: 2012-01 Impact factor: 17.425
Authors: Brandon J Perumpail; Muhammad Ali Khan; Eric R Yoo; George Cholankeril; Donghee Kim; Aijaz Ahmed Journal: World J Gastroenterol Date: 2017-12-21 Impact factor: 5.742
Authors: James Dahlhamer; Jacqueline Lucas; Carla Zelaya; Richard Nahin; Sean Mackey; Lynn DeBar; Robert Kerns; Michael Von Korff; Linda Porter; Charles Helmick Journal: MMWR Morb Mortal Wkly Rep Date: 2018-09-14 Impact factor: 17.586
Authors: Olufunso M Agbalajobi; Theresa Gmelin; Andrew M Moon; Wheytnie Alexandre; Grace Zhang; Walid F Gellad; Naudia Jonassaint; Shari S Rogal Journal: PLoS One Date: 2021-12-17 Impact factor: 3.240